MedPath

Phase II study of low-dose afatinib for elderly patients with non-small cell lung cancer harboring EGFR mutation (based on TDM)

Phase 2
Recruiting
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000022252
Lead Sponsor
Shizuoka Cancer Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
25
Inclusion Criteria

Not provided

Exclusion Criteria

1) Interstitial lung disease 2) Receiving continuous systemic corticosteroid 3) During pregnancy or lactation 4) Psychological disorder difficult to participate in this clinical study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath